Analyst consensus rating
Kailera Therapeutics Analyst Rating: none
Direct answer
Kailera Therapeutics's consensus rating is none.
5 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $42.40.
Forecast evidence checked September 3, 2026.
Get free Kailera Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $15.85
- Average price target
- $42.40
- High price target
- $57.00
- Low price target
- $30.00
- Low target gap
- +89.3%
- Target upside
- +167.5%
- High target gap
- +259.6%
- Target range width
- 170.3%
- Consensus rating
- none
- Analysts
- 5
- Evidence date
- September 3, 2026
- Valid through
- September 10, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Kailera Therapeutics?
Kailera Therapeutics has a verified none consensus. The same dataset has an average price target of $42.40.
How far are Kailera Therapeutics's low and high targets from the recorded price?
The low target implies +89.3%, while the high target implies +259.6%.
How many analysts are included in Kailera Therapeutics's consensus?
The verified consensus includes 5 analysts.
How is Kailera Therapeutics's target upside or downside calculated?
The average target of $42.40 is divided by the recorded price of $15.85, then one is subtracted to produce +167.5%. This does not guarantee a future return.
When was Kailera Therapeutics's analyst forecast verified?
The data was verified on 2026-09-03. The dataset is valid through 2026-09-10.